Savara Inc. Launches Early Access Program for Rare Lung Disease Treatment
LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) has unveiled the Savara Early Access Program, a significant initiative aimed at providing molgramostim to patients suffering from autoimmune pulmonary alveolar proteinosis (aPAP). This …
Savara Inc. Launches Early Access Program for Rare Lung Disease Treatment Read More